Table 2.
Characteristics of MS patients, split by treatmenta
| Data set | Discovery (318 arrays) |
Replication (183 arrays) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment | None (n = 62) |
IFN (n = 58) |
None (n = 27) |
IFN (n = 48) |
||||||||
| Visit | BL | F/U Y1 | F/U Y2 | BL | F/U Y1 | F/U Y2 | BL | F/U Y1 | F/U Y2 | BL | F/U Y1 | F/U Y2 |
| CIS/RR/SP (%) | 26/65/9 | 26/60/14 | 27/68/8 | 9/88/4 | 6/90/4 | 5/89/7 | 57/33/10 | 25/70/5 | 27/73/0 | 8/89/3 | 10/88/2 | 6/92/2 |
| Median disease duration (range) | 5.5 (0–32) | 7 (1–33) | 8 (2–32) | 7 (0–45) | 7 (1–46) | 8 (2–47) | 1 (0–22) | 2 (1–35) | 4 (2–14) | 7 (0–34) | 6 (1–35) | 7 (2–27) |
| Median EDSS (range) | 1 (0–6.5) | 2 (0–6.5) | 2 (0–6) | 1.5 (0–7) | 2 (0–7) | 2 (0–7) | 1 (0–5) | 1.5 (0–5.5) | 2 (0–5) | 1.5 (0–4) | 2.5 (0–6) | 2 (0–6) |
| Median age (range) | 43 (22–63) | 47 (27–64) | 48 (28–64) | 43 (23–66) | 43 (23–67) | 44 (24–66) | 45 (24–59) | 47 (25–62) | 46 (26–61) | 46 (23–61) | 45 (23–60) | 46 (25–61) |
| % Female | 76 | 74 | 70 | 67 | 69 | 70 | 57 | 60 | 73 | 71 | 66 | 63 |
| Number of subjects | 54 | 42 | 37 | 57 | 67 | 61 | 21 | 20 | 15 | 38 | 41 | 48 |
| Median time on IFN (range) (days) | NA | NA | NA | 737 (2–3511) | 849 (44–3895) | 1227 (50–4239) | NA | NA | NA | 956 (1–4171) | 1081 (16–4535) | 1233 (92–4902) |
BL, baseline; F/U Y1/Y2, follow-up year 1 or 2; CIS, clinically isolated syndrome; RR, relapsing–remitting; SP, secondary progressive; EDSS, Expanded Disability Status Scale; IFN, interferon; NA, not applicable.
aPatients' characteristics were determined at the start of the study.